Therapeutic Peptide-Programmed Liquid-Crystalline Topology Switching for pH-Gated Postoperative Cancer Immunotherapy.
Peptide-Programmed Liquid Crystals Tackle Postoperative Cancer
Adv Sci (Weinh)
by Yan Y, Chen B, Wang Y et al.
“Therapeutic Peptide-Programmed Liquid-Crystalline Topology Switching for pH-Gated Postoperative Cancer Immunotherapy. Yan Y(1)(2), Chen B(2), Wang Y(2), Hou Y(1), Ma Z(1), Yang Z(2), Yin X(1)(2), Chen Y(1), Huang L(1), Cai M(1), Liu X(1)(3), Zhu YZ(1), Ye L(1). Author information: (1)School of Pharmacy and Laboratory of Drug Discovery from Natural Resources and Industrialization, Macau University of Science and Technology, Macau, China. (2)Livzon Pharmaceutical Group Inc., National Engineering Research Center of Microsphere Technology for Controlled-Release Drug Delivery, Zhuhai, China. (3)Cancer Institute of the Affiliated Hospital of Qingdao University, Qingdao University, Qingdao, China. Stimuli-responsive depots for postoperative cancer therapy often treat therapeutic payloads as passive cargo, resulting in premature leakage and limited on-demand activation. Herein, we report a therapeutic peptide-programmed liquid-crystalline depot in which the Vpr-derived antitumor peptide (VDAP) functions simultaneously as an immunotherapeutic effector and a supramolecular topology regulator. At physiological pH, cationic α-helical VDAP was electrostatically anchored by oleic acid-containing lipid domains, reinforcing a compact inverse hexagonal (HII) topology associated with reduced peptide diffusion. In the acidic postoperative tumor microenvironment, protonation of oleic acid could disrupt anionic anchoring, whereas histidine protonation within VDAP amplified intrachannel electrostatic repulsion. This cooperative peptide-lipid charge reprogramming could drive graded liquid-crystalline topology remodeling from a diffusion-restrictive HII organization to a more interconnected bicontinuous cubic Im3̄m network, consistent with increased pH-responsive peptide release. In an orthotopic incomplete-resection breast tumor model, the depot induced immunogenic tumor destruction, enhanced damage-associated molecular pattern release, promoted dendritic cell maturation and CD8+ T cell infiltration, and reshaped the immunosuppressive surgical bed. These results demonstrate that electrostatic-topology-gated VDAP-enabled supramolecular topology switching provides effective adaptive local cancer immunotherapy, effectively suppressing postoperative tumor recurrence and attenuating pulmonary metastasis. © 2026 The Author(s). Advanced Science published by Wiley‐VCH GmbH.”
Peptide research just got a clever twist. Scientists in China have developed a liquid-crystalline depot that uses a therapeutic peptide to switch its structure and control release, all based on local pH. The team’s approach targets a real pain point in cancer immunotherapy: getting the right payload to the right place, at the right time, after surgery.
Their depot uses a Vpr-derived antitumor peptide (VDAP) that does double duty. It isn’t just a payload—it actively regulates the depot’s supramolecular structure. At normal body pH, VDAP binds to oleic acid lipids, locking the depot into a tight inverse hexagonal structure. This keeps peptide diffusion—and accidental leakage—low.
But cancer surgery sites are acidic. When the pH drops, the depot’s lipid-peptide bonds weaken and the structure shifts. The depot morphs into a more open, interconnected network (bicontinuous cubic). Result: the peptide releases faster, right where it’s needed, and not before.
What does this mean for cancer research? In a mouse model of breast tumor surgery, the pH-triggered depot ramped up antitumor immunity. Tumors were destroyed more thoroughly, immune cells flooded the surgical site, and lung metastases plummeted.
Key takeaway: This is next-level smart delivery. The peptide isn’t just along for the ride—it’s steering the ship.
Peptides as depot architects: not just “cargo”
Real-time, local control of release—no more one-size-fits-all delivery
Stronger immune activation and lower risk of cancer coming back
Researchers interested in advanced peptide delivery systems should check out this work. For more on the latest in peptide research, visit our index. This is the kind of innovation that keeps the peptide field moving forward.
Related Reading
One-Pot Fabrication of Pentapeptide Bio-Aerogel via Direct Alcogelation.
News · Eur J Obstet Gynecol Reprod BiolThe effect of glucagon-like peptide-1 receptor agonists versus metformin on pregnancy rates in women with polycystic ovary syndrome: a systematic review and meta-analysis of randomized trials.
News · Clin Chim ActaEvaluation of the commutability of control materials for C-peptide proficiency testing.
For Research Use Only
All content published on Pushing Peptides is intended for educational and informational purposes only. The information provided is not intended as medical advice, diagnosis, or treatment. Peptides discussed in this article are research compounds and are not approved for human therapeutic use by the FDA or any other regulatory agency. All studies referenced involve animal models or in vitro research unless otherwise stated. Consult a qualified healthcare professional before making any decisions related to your health. Pushing Peptides does not sell peptides — we are a vendor directory and educational resource.